Pulmo BioTech Inc.

Products:

 

Our current product portfolio contains a range of molecular imaging substances designed for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension, COPD and Lung Inflammatory disorders. The name of our Product Candidate is PulmoBind. We have completed pre-clinical Trials and we are currently seeking approval from our Regulatory Authority to commence Phase I Human Trials.

 

The company believes that our products will quickly replace the incumbent technology for the Nuclear Medicine based diagnosis of Pulmonary Embolism, and further create new markets for the diagnosis of Pulmonary Hypertension and other disorders of the pulmonary circulatory system.

 

What is our Product and why is this Interesting?

 

• PulmoBind is a patented radio-tracer marked peptide which will bond to the inner vascular wall of the Pulmonary Circulatory system after it has been administered intravenously
• Because the radio-tracer is a gamma emitter, the position and density of the PulmoBind molecules can be “seen” by a gamma camera (a piece of equipment available in every hospital’s Nuclear Medicine department)
• This will allow the 3D visualisation of Pulmonary Embolisms as well as the diagnosis of Pulmonary Hypertension and Chronic Obstructive Pulmonary Disorder
• Pulmonary Hypertension, Chronic Obstructive Pulmonary Disorder (COPD) and other medical problems afflicting the Pulmonary Circulation remain areas where there are no simple front-line diagnostic test – Orphan Conditions
• 200,000 people in the US alone die from Pulmonary Embolism each year
• Pulmonary Hypertension is frequently misdiagnosed or not diagnosed at all – early diagnosis might improve the survival rate dramatically
• There is currently no simple front-line diagnostic test for Pulmonary Hypertension
• PulmoBind can be used by any hospital that has a Nuclear Medicine Department (the majority of hospital worldwide plus a very large number of clinics)
• There will be no need for the hospitals to buy any extra capital equipment. Their existing Gamma Cameras will be all that is required
• There will be no need for hospitals to change any of their operational procedures to use PulmoBind
• The radio-marker used by PulmoBind is Tc99m – the most common medical radio-isotope in the world and available in every hospital with a Nuclear Medicine Department

 

Market Prospects for PulmoBind

 

• Main Market Areas are the Diagnosis of:

- Pulmonary Embolism

- Pulmonary Hypertension

- Chronic Obstructive Pulmonary Disorder (COPD)

- Lung Inflammatory Conditions

• Pulmonary Embolism Market is estimated to be worth $600 million per annum globally
• The markets for the other conditions that PulmoBind can diagnose do not exist as yet – how large could they become?
• PulmoBind has the potential to become a routine Front Line Diagnostic test
• Every time somebody tells their Doctor they have shortness of breath – prescribe a PulmoBind scan?
• Imagine the market if PulmoBind became as common a diagnostic tool as a chest x-ray
• So how big is the potential market for PulmoBind?

- Larger than $600 million per annum

- How much larger?

- $1 billion?    $2 billion?   More?

© 2011 Pulmo BioTech Incorporated